Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20

Safety and Tolerability of Histone Deacetylase (HDAC) Inhibitors in Oncology

(2019) Rashmi R. Shah   DRUG SAFETY

Progressive diffuse large B-cell lymphoma with TP53 gene mutation treated with chidamide-based chemotherapy

(2019) Qing Li et al.   Immunotherapy

Lower expression of Bax predicts poor clinical outcome in patients with glioma after curative resection and radiotherapy/chemotherapy

(2018) Pei-Guo Wang et al.   JOURNAL OF NEURO-ONCOLOGY

The Search for Potent, Small-Molecule HDACIs in Cancer Treatment: A Decade After Vorinostat

(2017) Chiara Zagni et al.   MEDICINAL RESEARCH REVIEWS

Chidamide in the treatment of peripheral T-cell lymphoma

(2017) Thomas Chan et al.   OncoTargets and Therapy

The HDAC inhibitor valproate induces a bivalent status of the CD20 promoter in CLL patients suggesting distinct epigenetic regulation of CD20 expression in CLL in vivo

(2017) Annarita Scialdone et al.   Oncotarget

Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research

(2016) Grzegorz S. Nowakowski et al.   JNCI-Journal of the National Cancer Institute

Activation of integrin α5 mediated by flow requires its translocation to membrane lipid rafts in vascular endothelial cells

(2016) Xiaoli Sun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Diffuse large B-cell lymphoma: R-CHOP failure--what to do?

(2016) B. Coiffier et al.   Hematology-American Society of Hematology Education Program

Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research

(2016) Grzegorz S. Nowakowski et al.   JNCI-Journal of the National Cancer Institute

A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma

(2015) R. Chen et al.   HAEMATOLOGICA

Histone Deacetylase Inhibitors: A Review on Class-I Specific Inhibition

(2015) Jagannath Behera et al.   MINI-REVIEWS IN MEDICINAL CHEMISTRY

A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma

(2015) R. Chen et al.   HAEMATOLOGICA

Extracellular HMGB1 promotes differentiation of nurse-like cells in chronic lymphocytic leukemia

(2014) L. Jia et al.   BLOOD

Postulated Mechanisms of Resistance of B-Cell Non-Hodgkin Lymphoma to Rituximab Treatment Regimens: Strategies to Overcome Resistance

(2014) Benjamin Bonavida   SEMINARS IN ONCOLOGY

Interaction of membrane/lipid rafts with the cytoskeleton: Impact on signaling and function

(2013) Brian P. Head et al.   BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES

Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma

(2013) Bjoern Chapuy et al.   CANCER CELL

Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas

(2012) Mei Dong et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Comparison of CD20 expression in B-cell lymphoma between newly diagnosed, untreated cases and those after rituximab treatment

(2012) Hiroaki Miyoshi et al.   CANCER SCIENCE

CD20 gene deletion causes a CD20-negative relapse in diffuse large B-cell lymphoma

(2012) Tsuyoshi Nakamaki et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Expression of FOXP3, CD68, and CD20 at Diagnosis in the Microenvironment of Classical Hodgkin Lymphoma Is Predictive of Outcome

(2012) Paul Greaves et al.   JOURNAL OF CLINICAL ONCOLOGY

Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity

(2011) Zhi-Qiang Ning et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection

(2010) S. A. Beers et al.   BLOOD

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma

(2010) Mark P. Chao et al.   CELL

Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma

(2010) Sean J. Whittaker et al.   JOURNAL OF CLINICAL ONCOLOGY

HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells

(2010) R Shimizu et al.   LEUKEMIA

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

(2010) R. Eric Davis et al.   NATURE

A unique chromatin signature uncovers early developmental enhancers in humans

(2010) Alvaro Rada-Iglesias et al.   NATURE

Histone H3K27ac separates active from poised enhancers and predicts developmental state

(2010) M. P. Creyghton et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance

(2009) J. Hiraga et al.   BLOOD

Phosphotyrosine protein dynamics in cell membrane rafts of sphingosine-1-phosphate-stimulated human endothelium: Role in barrier enhancement

(2009) Jing Zhao et al.   CELLULAR SIGNALLING

Chemical mechanisms of histone lysine and arginine modifications

(2008) Brian C. Smith et al.   Biochimica et Biophysica Acta-Gene Regulatory Mechanisms

Acquirement of Rituximab Resistance in Lymphoma Cell Lines Is Associated with Both Global CD20 Gene and Protein Down-Regulation Regulated at the Pretranscriptional and Posttranscriptional Levels

(2008) M. S. Czuczman et al.   CLINICAL CANCER RESEARCH

Origin and pathogenesis of nodular lymphocyte–predominant Hodgkin lymphoma as revealed by global gene expression analysis

(2008) Verena Brune et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Stromal Gene Signatures in Large-B-Cell Lymphomas

(2008) G. Lenz et al.   NEW ENGLAND JOURNAL OF MEDICINE